{
  "extraction_metadata": {
    "timestamp": "2025-10-02T17:07:55.654619",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 11,
    "total_picos": 15,
    "temperature": 0.1
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "patients with advanced NSCLC with a KRAS-G12C mutation that has progressed after at least one systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 7,
      "ContextTokens": 2924
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation should be treated according to Failure of at least one systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sotorasib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 2,
      "ContextTokens": 705
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 8,
      "ContextTokens": 2663
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": ""
        },
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel plus nintedanib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 12,
      "ContextTokens": 4689
    },
    "ES": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "ES",
      "PICOs": [],
      "ChunksUsed": 1,
      "ContextTokens": 294
    },
    "EU": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EU",
      "PICOs": [],
      "ChunksUsed": 1,
      "ContextTokens": 463
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 7,
      "ContextTokens": 2709
    },
    "IE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IE",
      "PICOs": [],
      "ChunksUsed": 1,
      "ContextTokens": 305
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "PICOs": [
        {
          "Population": "patients diagnosed with pre-treated, advanced-stage solid tumours with KRAS p.G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunotherapy alone or in combination with platinum-based chemotherapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 2,
      "ContextTokens": 506
    },
    "NL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with KRASG12C-mutated advanced NSCLC, who had disease progression after previous platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Docetaxel 75 mg/mÂ² intravenously every 3 weeks",
          "Outcomes": ""
        },
        {
          "Population": "patients with inoperable locally advanced or metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "erlotinib (150 mg orally daily at least 1 hour prior to and at least 2 hours after ingestion of food) in combination with tivantinib (360 mg orally twice daily with meals)",
          "Outcomes": ""
        },
        {
          "Population": "patients with inoperable locally advanced or metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "gemcitabine 1250mg/m2 days 1 and 8 every 21 days",
          "Outcomes": ""
        },
        {
          "Population": "patients with inoperable locally advanced or metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel 75 mg/m2 day 1 every 21 days",
          "Outcomes": ""
        },
        {
          "Population": "patients with inoperable locally advanced or metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed 500 mg/m2 day 1 every 21 days",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 4,
      "ContextTokens": 1487
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "patients with the KRAS G12C mutation are recommended treatment with sotorbasin following progression from prior systemic cytostatic and/or immune cell therapies",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorbasin",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 5,
      "ContextTokens": 1566
    }
  }
}